Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study

References

• Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med.346, 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch. Neurol.57, 418–420 (2000).
   PubMed Web of Science ®Google Scholar
• Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia27, 394–402 (2007).
   PubMed Web of Science ®Google Scholar
• Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravating factors of migraine vs. tension-type headache. Headache41, 554–558 (2001).
   PubMed Web of Science ®Google Scholar
• Henry P, Auray JP, Gaudin AF et al. Prevalence and clinical characteristics of migraine in France. Neurology59, 232–237 (2002).
   PubMed Web of Science ®Google Scholar
• Bener A, Uduman SA Qassimi EM et al. Genetic and environmental factors associated with migraine in schoolchildren. Headache40, 152–157 (2000).
   PubMed Web of Science ®Google Scholar
• Joubert J. Migraine diagnosis and treatment. Aust. Fam. Physician.34(8), 627–632 (2005).
   PubMedGoogle Scholar
• Levy D, Straussman AM, Burstein R. A critical view on the role of migraine triggers in the genesis of migraine pain. Headache49(6), 953–957 (2009).
   PubMed Web of Science ®Google Scholar
• Moskowitz DA. Defining a pathway to discovery from bench to bedside: the trigeminovascular system and sensitization. Headache48, 688–690 (2008).
   PubMed Web of Science ®Google Scholar
• Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience106, 793–800 (2001).
   PubMed Web of Science ®Google Scholar
• Knight YE, Bartsch T, Kaube K, Goadsby PJ. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J. Neurosci.22, RC213 (2002).
   PubMed Web of Science ®Google Scholar
• Fields HL. Pain modulation: expectation, opidio analgesia and virtual pain. Prog. Brain Res.122, 245–253 (2000).
   PubMed Web of Science ®Google Scholar
• Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci.25, 319–325 (2002).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Migraine triggers. Headache49(6), 958–961 (2009).
   PubMedGoogle Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22, 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia20, 687–694 (2000).
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann. NY Acad. Sci.600, 587–598 (1990).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu. Rev. Med.44, 145–154 (1993).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The pathophysiology of headache. In: Wolff’s Headache And Other Head Pain (7th Edition). Silberstein SD, Lipton RB, Soloman S (Eds). Oxford University Press, Oxford, UK, 57–72 (2001).
   Google Scholar
• Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia21, 804–812 (2001).
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acuste treatment of multiple migraine attacks: results of a large randomized, double-blind placebo-controlled study. Cephalalgia20, 588–596 (2000).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The ‘Act when mild’ (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia28(2), 36–41 (2008).
   PubMed Web of Science ®Google Scholar
• Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur. Neurol.31, 295–299 (1991).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Block G, Dahlöf C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia20, 765–786 (2000).
   PubMed Web of Science ®Google Scholar
• Cady RK, Lipton RB, Hall C, Stewart WF, O’Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferes: results of the Spectrum Study. Headache40, 792–797 (2000).
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther.22, 1035–1048 (2000).
   PubMed Web of Science ®Google Scholar
• Ng-Mak DS, Cady R, Chen YT, Ma L, Bell CF, Hu XH. Can migraineurs accurately identify their headaches as ‘migraine’ at attack onset? Headache.47(5), 645–653 (2007).
   PubMed Web of Science ®Google Scholar
• Linde M, Mellberg A, Dahlöf C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia26(6), 712–721 (2006).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache47(2), 189–198 (2007).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zanchin G, Geraud G et al. Early vs. non-early intervention in acute migraine-’Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia28(4), 383–391 (2008).
   PubMed Web of Science ®Google Scholar
• Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache46, 715–725 (2006).
   PubMed Web of Science ®Google Scholar
• Shapero G, Dowson A, Lacoste JP, Almqvist P. Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. Int. J. Clin. Pract.60, 1530–1535 (2006).
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M, Díaz-Insa S, Leone M, Vila C, Clissold SP. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int. J. Clin. Pract.64, 936–943 (2010).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The International Classification of headache Disorders. 2nd Edition. Cephalalgia24(Suppl. 1), 1–160 (2004).
   Web of Science ®Google Scholar
• Géraud G, Lanteri-Minet M, Lucas C; French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin. Ther.26, 1305–1318 (2004).
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Willheim K, Sepic-Grahovac D et al. Migraine and tension-type headache in Croatia: a population-based survey of precipitating factors. Cephalalgia23, 336–343 (2003).
   PubMed Web of Science ®Google Scholar
• Turner LC, Molgaard CA, Gardner CH, Rothrock JF, Stang PE. Migraine trigger factors in non-clinical Mexican–American population in San Diego county: implications for etiology. Cephalalgia15, 523–530 (1995).
   PubMed Web of Science ®Google Scholar
• Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain53, 65–72 (1993).
   PubMed Web of Science ®Google Scholar
• Chabriat H, Danchot J, Michel P, Joire JE, Henry P. Precipitating factors of headache. A prospective study in a national control-matched survey in migraineurs and nonmigraineurs. Headache39, 335–338 (1999).
   PubMed Web of Science ®Google Scholar
• Ierusalimschy R, Moreira Filho PF. Precipitating factors of migraine attacks in patients with migraine without aura. Arq. Neuropsiquiatr.60, 609–613 (2002).
   PubMed Web of Science ®Google Scholar
• Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache44, 865–872 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J. Health Soc. Behav.24, 385–396 (1983).
   PubMed Web of Science ®Google Scholar
• Radat F, Mekies C, Géraud G. Anxiety, stress and coping behaviours in primary care migraine patients: results of the SMILE study. Cephalalgia28(11), 1115–1125 (2008).
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache43(1), 19–26 (2003).
   PubMed Web of Science ®Google Scholar
• Marcus D. Chronic headache: the importance of trigger identification. Headache Pain14, 139–144 (2003).
   Google Scholar
• Scher AI, Midgette, Lipton RB. Risk factors for headache chronification. Headache48, 16–25 (2008).
   PubMed Web of Science ®Google Scholar
• Martin PR. How do trigger factors acquire the capacity to precipitate headaches? Behav. Res. Ther.39, 545–554 (2001).
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol. Sci.27(2), S193–S197 (2006).
   PubMed Web of Science ®Google Scholar
• Allais G, Castagnoli Gabellari I, De Lorenzo C, Mana O, Benedetto C. Menstrual migraine: clinical and therapeutic aspects. Expert Rev. Neurother.7(9), 1105–1120 (2007).
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Bonellie G, Kagasniemi P, Pascual J, Schuaib A. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study group. Obstet. Gynecol.86(6), 911–916 (1995).
   PubMed Web of Science ®Google Scholar
• Landy S, Savani N, Schackelford SJ, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild phase of menstrually associated migraine. Int. J. Clin. Pract.58(10), 913–919 (2004).
   PubMed Web of Science ®Google Scholar
• Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache44(2), 120–130 (2004).
   PubMed Web of Science ®Google Scholar
• Nett R, Landy S, Shackleford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet. Gynecol.102(4), 835–842 (2003).
   PubMed Web of Science ®Google Scholar
• Silberstein S. The efficacy of zolmitriptan is unaffected by relationship to menses. Cephalalgia21(4), 241–248 (2001).
   PubMed Web of Science ®Google Scholar
• Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur. J. Neurol.12(10), 774–781 (2005).
   PubMed Web of Science ®Google Scholar
• Lambert GA, Zagami AS. The mode of action of migraine triggers: a hypothesis. Headache49, 253–275 (2009).
   PubMed Web of Science ®Google Scholar
• Sobel N, Prabhakaran V, Zhao Z et al. Time course of odorant-induced activation in the human primary olfactory cortex. J. Neurophysiol.83, 537–551 (2000).
   PubMed Web of Science ®Google Scholar
• Piper R. Effects of spreading depression on physiological activation of the cerebral cortex in the cat. In: Migraine And Other Headaches: The Vascular Symptoms. Olesen J (Ed.). Raven Press, NY, USA, 177–180 (1991).
   Google Scholar
• Dietrich T, Krings T, Neulen J et al. Effects of blood estrogen level on cortical activation patterns during cognitive activation as measured by function MRI. Neuroimage13, 425–432 (2001).
   PubMed Web of Science ®Google Scholar
• Chakravarty A. How triggers trigger acute migraine attacks: a hypothesis. Med. Hypotheses74(4), 750–753 (2010).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AZERT 12.5 mg time versus intensity migraine study (AIMS). Headache47, 519–530 (2007).
   PubMed Web of Science ®Google Scholar
• Edmeads J. Understanding the needs of migraine patients. Drugs66(Suppl. 3), 1–8 (2006).
   Web of Science ®Google Scholar
• Meyer H. Pharmacological management for the adult migraine sufferer. J. Neurosci. Nurs.41(6), 348–352 (2009).
   PubMed Web of Science ®Google Scholar
• Foley KA, Cady R, Martin V. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache45(5), 538–545 (2005).
   PubMed Web of Science ®Google Scholar
• Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia28(Suppl. 2), 28–35 (2008).
   PubMedGoogle Scholar
• Dodick DW. Applying the benefits of the AwM study in the clinic. Cephalalgia28(Suppl. 2), 42–49 (2008).
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache43(1), 36–43 (2003).
   PubMed Web of Science ®Google Scholar